A defined TGFβ response gene signature is now being used to subtype CRC; consensus molecular subtype 4 (CMS4) CRC displays elevated TGFβ signaling activity, which confers a poor prognosis, higher relapse rates, and limited response to receptor tyrosine kinase therapy4,7,8. This evidence concerns the gene NTRK1 and colorectal carcinoma.